Drugs /
anti-hcd70 car t cells
Overview
Clinical Trials
Anti-hcd70 car t cells has been investigated in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial investigating anti-hcd70 car t cells, 1 is phase 1/phase 2 (0 open).
CD70 Expression is the most frequent biomarker inclusion criterion for anti-hcd70 car t cells clinical trials.
Malignant solid tumor is the most common disease being investigated in anti-hcd70 car t cells clinical trials [2].
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].
2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.